Indian drug formulation market grows 15.3% in Aug

Indian companies grew by 17.1% against 9% growth for MNC pharma companies during the month

Image via Shutterstock
<a href="http://www.shutterstock.com/pic-228848833/stock-photo-pills-drug.html" target="_blank">Image</a> via Shutterstock
Press Trust of India Mumbai
Last Updated : Sep 25 2016 | 1:38 PM IST
The domestic formulation drug market grew by 15.3% in August to Rs 9,643 crore over the corresponding month last year.

The growth was driven by 9.1% expansion in volumes, 2.9% rise in prices and 3.3% in new launches, according to the data compiled by pharma market research company AIOCD AWACS.

Indian companies grew by 17.1% against 9% growth for MNC pharma companies during the month.

Amongst the top 50 MNCs, Janssen grew by 23.2% followed by Sanofi at 13.4% and Abbott at 12.6% over the same month last year.

Among the top 50 Indian corporates, Centaur had the highest growth rate at 42.5% followed by Bharat Serums at 34.4%, Apex at 34% and Indoco Remedies at 33.7%.

Following the regulatory ban on fixed dose combination, this segment showed a huge volume de-growth of 16.8%. In revenue terms, Indian companies degrew by 11.1% in the FDC portfolio whereas the MNCs degrew by 16.1%, the data said.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 25 2016 | 1:15 PM IST

Next Story